Corporate calendar for Vertex Pharmaceuticals Incorporated (VRTX): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-11-02 | $4.76 | $3.41B |
| 2026-08-03 | $4.74 | $3.23B |
| 2026-05-04 | $4.24 | $2.99B |
| 2026-02-12 | $5.11 | $3.18B |
| 2025-11-03 | $4.57 | $3.06B |
| 2025-08-04 | $4.29 | $2.91B |
| 2025-05-05 | $4.25 | $2.86B |
Stock Splits
| Date | Ratio |
|---|---|
| 2000-08-24 | 2:1 |
Price
| Price | $503.50 |
| Market Cap | $127.8B |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 48 |
| Hold | 7 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 56 |
| Avg rating (1-5) | 0.84 |
Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT
Explore sector: Healthcare · Biotechnology
More sections of VRTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks